Department of Internal Medicine ASL Salerno, "Santa Maria della Speranza" Hospital, Salerno, Italy; Postgraduate Program in Allergy and Clinical Immunology, University of Naples Federico II, Naples, Italy.
Respiratory Medicine Unit, University "Magna Græcia" of Catanzaro, Catanzaro, Italy.
Respir Med. 2022 Aug-Sep;200:106916. doi: 10.1016/j.rmed.2022.106916. Epub 2022 Jun 27.
Patients with respiratory diseases suffer more from problems of severe psychiatric comorbidity than the general population. Asthma might cause psychiatric disorders and affect patients' quality of life negatively. Previous studies reported that mental disorders prevail in asthmatic patients, causing anxiety, depression, and suicidal risk. The aim of this study is to evaluate in real life the prevalence of psychological comorbidities in asthmatics with severe asthma treated by biologicals (Benralizumab, Mepolizumab, Omalizumab). This study starts with the hypothesis that psychological distress, anxiety, depression and suicidal risk in severe asthma patients decreases if treated by biologicals. This study involves a sample of 90 patients (32 males, 58 females and aged 53.92 ± 15.92) suffering from severe asthma and treated with the biological drugs of Benralizumab, Mepolizumab, Omalizumab during Covid-19 pandemic. At the beginning of the treatment (T0) and after 16 weeks (T1), there have been reported results from both clinical disease control, assessed using the ACT, and psychological disorders, assessed with the PSS, HADS and C-SSRS. In the sample of these patients treated with biologicals for severe asthma, the study reported a significant change in all observed parameters, including asthma control (ACT), stress (PSS), anxiety (HADS-A) and depressive symptoms (HADS-D, despite Covid-19 pandemic. In addition, there was a significant improvement in disease management, perceived stress, anxiety and depressive symptoms after a 16 week treatment for severe asthma, independent from the type of biologic drugs used during the pandemic.
患有呼吸系统疾病的患者比一般人群更易受到严重精神共病问题的困扰。哮喘可能导致精神障碍，并对患者的生活质量产生负面影响。先前的研究报告称，精神障碍在哮喘患者中较为普遍，导致焦虑、抑郁和自杀风险增加。本研究旨在真实评估生物制剂（贝那利珠单抗、美泊利珠单抗、奥马珠单抗）治疗的重度哮喘患者中心理共病的患病率。本研究基于以下假设：如果用生物制剂治疗，重度哮喘患者的心理困扰、焦虑、抑郁和自杀风险会降低。本研究涉及 90 名（32 名男性，58 名女性，年龄 53.92±15.92）患有重度哮喘并在新冠疫情期间接受贝那利珠单抗、美泊利珠单抗、奥马珠单抗治疗的患者。在治疗开始时（T0）和 16 周后（T1），报告了使用 ACT 评估的临床疾病控制和使用 PSS、HADS 和 C-SSRS 评估的心理障碍的结果。在接受生物制剂治疗重度哮喘的患者样本中，研究报告称，所有观察到的参数都发生了显著变化，包括哮喘控制（ACT）、压力（PSS）、焦虑（HADS-A）和抑郁症状（HADS-D），尽管存在新冠疫情。此外，在新冠疫情期间，重度哮喘的 16 周治疗后，疾病管理、感知压力、焦虑和抑郁症状都有显著改善，且与所使用的生物制剂类型无关。
